Gestational diabetes & diabetes in pregnancy
Cost effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects ( EMERGE )—A randomised placebo‐controlled clinical trial
Authors' conclusion
We do not find definitive evidence that early initiation of metformin in addition to usual care for GDM was more cost-effective than usual care alone. The clinical and economic evidence may be considered equivocal, but worthy of further examination.
Study context
- Population
- Women with gestational diabetes mellitus (GDM)randomised
- Participants
- 535 women
- Comparison
- Early metformin plus usual care vs placebo plus usual care
- Primary endpoint
- Incremental healthcare costs and QALYs; expected cost-effectiveness at thresholds of €20,000, €45,000 and €100,000 per QALY gained
Methodological detailshealthcare perspective, placebo-controlled, Uncertainty explored using parametric, non-parametric, deterministic and probabilistic methods
- Healthcare perspective
- Placebo-controlled
- Uncertainty explored using parametric, non-parametric, deterministic and probabilistic methods
Primary result
As reported in the abstract
Mean increase in costs
193.07 €
95% CI -€789.88, €1176.01P = 0.700
Early metformin
Mean increase in quality adjusted life years (QALYs)
0.002 QALYs
95% CI −0.009 to 0.013P = 0.771
Early metformin
- Probability of early metformin being more cost-effective at €20,000 per QALY
- 0.423
- Probability of early metformin being more cost-effective at €45,000 per QALY
- 0.452
- Probability of early metformin being more cost-effective at €100,000 per QALY
- 0.524
Further findings
- More favourable but not definitive evidence for early metformin in cohorts with previous GDM and previous caesarean section
- Exploratory subgroup analyses
Original publication
Cost effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects ( EMERGE )—A randomised placebo‐controlled clinical trial. Diabet Med. Published 2 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →